MIP is focussed on developing synthetic antibodies made from molecularly imprinted polymers (MIPs) that can be used in applications where antibodies traditionally struggle. MIPs have successfully been created and deployed against all major target classes including peptides, proteins and other macromolecular structures, as well as smaller chemical entities such as drugs, their metabolites and commonly used biochemical species such as enzyme cofactors.
Meet the team
Downing LLP launches 'knowledge intensive' EIS fund to fuel entrepreneurial healthcare businesses in wake of Covid-19
Specialist tax-efficient investment manager Downing LLP is pleased to announce the launch of a new Enterprise ...